董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christian Henry | 男 | Director | 53 | 67.11万美元 | 未持股 | 2021-09-16 |
| Reshma Kewalramani | 女 | Director | 49 | 未披露 | 未持股 | 2021-09-16 |
| Shyam Sankar | 男 | Director | 39 | 67.11万美元 | 未持股 | 2021-09-16 |
| Jason Kelly | -- | Chief Executive Officer, Founder and Director | 40 | 1053.32万美元 | 未持股 | 2021-09-16 |
| Reshma Shetty | -- | President, Chief Operating Officer, Founder and Director | 40 | 1053.37万美元 | 未持股 | 2021-09-16 |
| Marijn Dekkers | 男 | Director,Chairman | 63 | 未披露 | 未持股 | 2021-09-16 |
| Harry E. Sloan | 男 | Director | 71 | 未披露 | 未持股 | 2021-09-16 |
| Arie Belldegrun | 男 | Director | 71 | 未披露 | 未持股 | 2021-09-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jason Kelly | -- | Chief Executive Officer, Founder and Director | 40 | 1053.32万美元 | 未持股 | 2021-09-16 |
| Reshma Shetty | -- | President, Chief Operating Officer, Founder and Director | 40 | 1053.37万美元 | 未持股 | 2021-09-16 |
| Mark Dmytruk | 男 | Chief Financial Officer | 50 | 6.66万美元 | 未持股 | 2021-09-16 |
董事简历
中英对照 | 中文 | 英文- Christian Henry
-
Christian Henry自2016年11月起担任董事，自2017年10月起担任董事会主席。Henry先生还担任Ginkgo Bioworks（一家私人合成生物学公司）和Pacific Biosciences（一家上市的生命科学公司）的董事会成员。Henry先生曾于2015年至2017年1月担任Illumina，Inc.执行Vice President兼首席商务官，此前曾于2014年至2015年担任高级副总裁兼首席商务官，2012年至2014年担任高级副总裁基因组解决方案总经理高级副总裁，2010年至2012年，担任生命科学首席财务官和总经理；2009年至2010年，担任企业发展和首席财务官高级副总裁，；2007年至2009年，担任高级副总裁和首席财务官；2005年至2006年，担任Vice President和首席财务官。在加入Illumina，Inc.之前，Henry先生从2003年到2005年担任Tickets.com，Inc.的首席财务官。从1999年到2003年，Henry先生担任赛默飞世尔科技（Thermo Fisher Scientific）于2016年收购的Affymetrix，Inc.的Vice President、财务与公司财务总监。1997年，Henry先生加入Nektar Therapeutics（前身为Inhale Therapeutic Systems，Inc.），担任公司财务总监，后来从1997年到1999年担任其首席会计官。Henry先生于1996年担任Sugen，Inc.的总会计经理。他的职业生涯始于1992年任职Ernst&Young LLP，在那里他曾担任高级会计师（直到1996年）。Henry先生在加州大学圣地亚哥分校（University of California，San Diego）获得生物化学和细胞生物学学士学位，并在加州大学欧文分校（University of California，Irvine）获得金融工商管理硕士学位。
Christian Henry,has served as a director since November 2016, and as Chairman of Wave Life Sciences Ltd. Board since October 2017. Mr. Henry currently serves as the President and Chief Executive Officer of Pacific Biosciences, a publicly traded life sciences company, a position he has held since September 2020, and has also served on its board of directors since 2018. Mr. Henry has served on the board of directors of Ginkgo Bioworks, a publicly-traded synthetic biology company, since 2016, and previously served on the board of directors CM Life Sciences III Inc., a publicly-traded special purpose acquisition company, from April 2021 through December 2021. Mr. Henry served as Executive Vice President & Chief Commercial Officer of Illumina, Inc. from 2015 through January 2017, and previously served as Senior Vice President & Chief Commercial Officer from 2014 to 2015, Senior Vice President & General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial Officer & General Manager Life Sciences from 2010 to 2012, Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010, Senior Vice President & Chief Financial Officer from 2007 to 2009, and Vice President & Chief Financial Officer from 2005 to 2006. Prior to joining Illumina, Inc., Mr. Henry served as the Chief Financial Officer of Tickets.com, Inc. from 2003 to 2005. From 1999 to 2003, Mr. Henry served as Vice President, Finance & Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr. Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later as its Chief Accounting Officer from 1997 to 1999. In 1996, Mr. Henry served as General Accounting Manager of Sugen, Inc. Mr. Henry began his career in 1992 at Ernst & Young LLP, where he was a Senior Accountant through 1996. Mr. Henry earned his B.A. in biochemistry and cell biology from the University of California, San Diego, and his M.B.A., with a concentration in finance, from the University of California, Irvine. - Christian Henry自2016年11月起担任董事，自2017年10月起担任董事会主席。Henry先生还担任Ginkgo Bioworks（一家私人合成生物学公司）和Pacific Biosciences（一家上市的生命科学公司）的董事会成员。Henry先生曾于2015年至2017年1月担任Illumina，Inc.执行Vice President兼首席商务官，此前曾于2014年至2015年担任高级副总裁兼首席商务官，2012年至2014年担任高级副总裁基因组解决方案总经理高级副总裁，2010年至2012年，担任生命科学首席财务官和总经理；2009年至2010年，担任企业发展和首席财务官高级副总裁，；2007年至2009年，担任高级副总裁和首席财务官；2005年至2006年，担任Vice President和首席财务官。在加入Illumina，Inc.之前，Henry先生从2003年到2005年担任Tickets.com，Inc.的首席财务官。从1999年到2003年，Henry先生担任赛默飞世尔科技（Thermo Fisher Scientific）于2016年收购的Affymetrix，Inc.的Vice President、财务与公司财务总监。1997年，Henry先生加入Nektar Therapeutics（前身为Inhale Therapeutic Systems，Inc.），担任公司财务总监，后来从1997年到1999年担任其首席会计官。Henry先生于1996年担任Sugen，Inc.的总会计经理。他的职业生涯始于1992年任职Ernst&Young LLP，在那里他曾担任高级会计师（直到1996年）。Henry先生在加州大学圣地亚哥分校（University of California，San Diego）获得生物化学和细胞生物学学士学位，并在加州大学欧文分校（University of California，Irvine）获得金融工商管理硕士学位。
- Christian Henry,has served as a director since November 2016, and as Chairman of Wave Life Sciences Ltd. Board since October 2017. Mr. Henry currently serves as the President and Chief Executive Officer of Pacific Biosciences, a publicly traded life sciences company, a position he has held since September 2020, and has also served on its board of directors since 2018. Mr. Henry has served on the board of directors of Ginkgo Bioworks, a publicly-traded synthetic biology company, since 2016, and previously served on the board of directors CM Life Sciences III Inc., a publicly-traded special purpose acquisition company, from April 2021 through December 2021. Mr. Henry served as Executive Vice President & Chief Commercial Officer of Illumina, Inc. from 2015 through January 2017, and previously served as Senior Vice President & Chief Commercial Officer from 2014 to 2015, Senior Vice President & General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial Officer & General Manager Life Sciences from 2010 to 2012, Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010, Senior Vice President & Chief Financial Officer from 2007 to 2009, and Vice President & Chief Financial Officer from 2005 to 2006. Prior to joining Illumina, Inc., Mr. Henry served as the Chief Financial Officer of Tickets.com, Inc. from 2003 to 2005. From 1999 to 2003, Mr. Henry served as Vice President, Finance & Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr. Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later as its Chief Accounting Officer from 1997 to 1999. In 1996, Mr. Henry served as General Accounting Manager of Sugen, Inc. Mr. Henry began his career in 1992 at Ernst & Young LLP, where he was a Senior Accountant through 1996. Mr. Henry earned his B.A. in biochemistry and cell biology from the University of California, San Diego, and his M.B.A., with a concentration in finance, from the University of California, Irvine.
- Reshma Kewalramani
-
Reshma Kewalramani自2020年4月起担任Vertex Pharmaceuticals Incorporated首席执行官兼总裁，自2020年2月起担任Vertex Pharmaceuticals Incorporated董事会成员。Kewalramani博士于2018年4月至2020年4月期间担任Vertex Pharmaceuticals Incorporated执行副总裁兼首席医疗官。2017年2月至2018年4月，她担任Vertex Pharmaceuticals Incorporated高级副总裁，负责后期开发。2004年8月至2017年1月，她在Amgen Inc.担任越来越重要的职务，最近一次担任副总裁兼美国医疗组织负责人。从2014年到2019年，Kewalramani博士是FDA内分泌和代谢药物咨询委员会的行业代表。Kewalramani博士自2021年9月起还担任Ginkgo Bioworks董事会成员。她在马萨诸塞州总医院完成了内科实习和住院实习，并在马萨诸塞州综合医院和布里格姆妇女医院联合项目完成了肾脏病研究。Kewalramani博士拥有波士顿大学的学士学位和波士顿大学医学院的医学博士学位。Kewalramani博士还完成了哈佛商学院的综合管理课程，是该校的校友。
Reshma Kewalramani,Chief Executive Officer and President of Vertex Pharmaceuticals Incorporated since April 2020;Executive Vice President and Chief Medical Officer of Vertex from 2018 through March 2020;Senior Vice President, Late Development of Vertex from 2017 until 2018;Member of the Board of Directors of Ginkgo Bioworks Holdings, Inc., a publicly traded biotechnology company, from 2021 to 2024;Served in roles of increasing responsibility at Amgen Inc. from 2004 to 2017, most recently as Vice President and Head of U.S. Medical Organization;Industry representative to the FDA's Endocrine and Metabolic Drug Advisory Committee from 2014 through 2019;Holds a B.A. from Boston University and an M.D. from Boston University School of Medicine; Dr. Kewalramani completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Women's Hospital combined program;Dr. Kewalramani is an alumna of the Harvard Business School, having completed the General Management Program. - Reshma Kewalramani自2020年4月起担任Vertex Pharmaceuticals Incorporated首席执行官兼总裁，自2020年2月起担任Vertex Pharmaceuticals Incorporated董事会成员。Kewalramani博士于2018年4月至2020年4月期间担任Vertex Pharmaceuticals Incorporated执行副总裁兼首席医疗官。2017年2月至2018年4月，她担任Vertex Pharmaceuticals Incorporated高级副总裁，负责后期开发。2004年8月至2017年1月，她在Amgen Inc.担任越来越重要的职务，最近一次担任副总裁兼美国医疗组织负责人。从2014年到2019年，Kewalramani博士是FDA内分泌和代谢药物咨询委员会的行业代表。Kewalramani博士自2021年9月起还担任Ginkgo Bioworks董事会成员。她在马萨诸塞州总医院完成了内科实习和住院实习，并在马萨诸塞州综合医院和布里格姆妇女医院联合项目完成了肾脏病研究。Kewalramani博士拥有波士顿大学的学士学位和波士顿大学医学院的医学博士学位。Kewalramani博士还完成了哈佛商学院的综合管理课程，是该校的校友。
- Reshma Kewalramani,Chief Executive Officer and President of Vertex Pharmaceuticals Incorporated since April 2020;Executive Vice President and Chief Medical Officer of Vertex from 2018 through March 2020;Senior Vice President, Late Development of Vertex from 2017 until 2018;Member of the Board of Directors of Ginkgo Bioworks Holdings, Inc., a publicly traded biotechnology company, from 2021 to 2024;Served in roles of increasing responsibility at Amgen Inc. from 2004 to 2017, most recently as Vice President and Head of U.S. Medical Organization;Industry representative to the FDA's Endocrine and Metabolic Drug Advisory Committee from 2014 through 2019;Holds a B.A. from Boston University and an M.D. from Boston University School of Medicine; Dr. Kewalramani completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Women's Hospital combined program;Dr. Kewalramani is an alumna of the Harvard Business School, having completed the General Management Program.
- Shyam Sankar
-
Shyam Sankar自2006年以来担任Palantir Technologies Inc.首席运营官和执行副总裁，一直担任Palantir Technologies Inc.的各种职位。Sankar先生拥有康奈尔大学电气与计算机工程学士学位，斯坦福大学管理科学与工程硕士学位。
Shyam Sankar,has served in various positions with since 2006, most recently as Chief Technology Officer ("CTO") and Executive Vice President. Mr. Sankar holds a B.S. in Electrical and Computer Engineering from Cornell University and a M.S. in Management Science and Engineering from Stanford University. - Shyam Sankar自2006年以来担任Palantir Technologies Inc.首席运营官和执行副总裁，一直担任Palantir Technologies Inc.的各种职位。Sankar先生拥有康奈尔大学电气与计算机工程学士学位，斯坦福大学管理科学与工程硕士学位。
- Shyam Sankar,has served in various positions with since 2006, most recently as Chief Technology Officer ("CTO") and Executive Vice President. Mr. Sankar holds a B.S. in Electrical and Computer Engineering from Cornell University and a M.S. in Management Science and Engineering from Stanford University.
- Jason Kelly
-
Jason Kelly，我们的创始人之一，自2008年成立以来担任我们的董事会成员和首席执行官。Kelly博士曾担任CM Life Sciences IIInc.董事纳斯达克:CMII，一家专注于生命科学领域的特殊目的收购公司，自2021年2月首次公开募股以来。Kelly博士拥有麻省理工学院生物工程博士学位和化学工程和生物学学士学位。
Jason Kelly,one of our founders, has served as a member of our board of directors and as the Chief Executive Officer since Ginkgo’s founding in 2008. Dr. Kelly has served as a director of CM Life Sciences II Inc. Nasdaq: CMII, a special purpose acquisition company with a focus on the life sciences sector, since its initial public offering in February 2021. Dr. Kelly has a Ph.D. in Biological Engineering and a B.S. in Chemical Engineering and Biology from the Massachusetts Institute of Technology. - Jason Kelly，我们的创始人之一，自2008年成立以来担任我们的董事会成员和首席执行官。Kelly博士曾担任CM Life Sciences IIInc.董事纳斯达克:CMII，一家专注于生命科学领域的特殊目的收购公司，自2021年2月首次公开募股以来。Kelly博士拥有麻省理工学院生物工程博士学位和化学工程和生物学学士学位。
- Jason Kelly,one of our founders, has served as a member of our board of directors and as the Chief Executive Officer since Ginkgo’s founding in 2008. Dr. Kelly has served as a director of CM Life Sciences II Inc. Nasdaq: CMII, a special purpose acquisition company with a focus on the life sciences sector, since its initial public offering in February 2021. Dr. Kelly has a Ph.D. in Biological Engineering and a B.S. in Chemical Engineering and Biology from the Massachusetts Institute of Technology.
- Reshma Shetty
-
Reshma Shetty，我们的创始人之一，自2008年成立以来担任我们的董事会成员，总裁兼首席运营官。谢蒂博士目前在非营利组织“核威胁倡议”的生物咨询小组任职。谢蒂博士拥有麻省理工学院生物工程博士学位和犹他大学计算机科学学士学位。
Reshma Shetty,one of our founders, has served as a member of our board of directors and as President and Chief Operating Officer since Ginkgo’s founding in 2008. Dr. Shetty currently serves on the Bio Advisory Group at the non-profit Nuclear Threat Initiative. Dr. Shetty has a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology and a B.S. in Computer Science from the University of Utah. - Reshma Shetty，我们的创始人之一，自2008年成立以来担任我们的董事会成员，总裁兼首席运营官。谢蒂博士目前在非营利组织“核威胁倡议”的生物咨询小组任职。谢蒂博士拥有麻省理工学院生物工程博士学位和犹他大学计算机科学学士学位。
- Reshma Shetty,one of our founders, has served as a member of our board of directors and as President and Chief Operating Officer since Ginkgo’s founding in 2008. Dr. Shetty currently serves on the Bio Advisory Group at the non-profit Nuclear Threat Initiative. Dr. Shetty has a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology and a B.S. in Computer Science from the University of Utah.
- Marijn Dekkers
-
自2021年6月完成业务合并以来，他一直担任Quantum-Si Incorporated董事会成员。自2017年5月以来，德克斯博士一直担任生命科学行业投资和咨询公司Novalis LifeSciences LLC的创始人和董事长。2010年1月至2016年5月，Dekkers博士担任德国勒沃库森拜耳公司的首席执行官，2002年至2009年，他担任赛默飞世尔科技公司。Dekkers博士目前担任乔治城大学国立卫生研究院基金会、Cerevel Therapeutics Holdings, Inc.、Ginkgo Bioworks Holdings, Inc.和AdBiome有限责任公司的董事。Dekkers博士曾于2017年3月至2021年9月担任Quanterix Corporation董事会成员。Dekkers博士在埃因霍温大学获得化学工程博士和硕士学位，在荷兰的拉德布德大学获得化学学士学位。
Marijn Dekkers,has served on Quantum-Si Incorporated board of directors since the Closing of the Business Combination in June 2021. Since May 2017, Dr. Dekkers has served as a founder and the Chairman of Novalis LifeSciences LLC,an investment and advisory firm for the life sciences industry. From January 2010 to May 2016, Dr. Dekkers served as Chief Executive Officer of Bayer AG in Leverkusen, Germany, and from 2002 to 2009, he was chief executive officer of Thermo Fisher Scientific Inc. Dr. Dekkers currently serves on the board of directors of the Foundation for the National Institutes of Health, Georgetown University, Cerevel Therapeutics Holdings, Inc., Ginkgo Bioworks Holdings, Inc., and AdBiome LLC. Dr. Dekkers previously served on the board of directors of Quanterix Corporation from March 2017 to September 2021. Dr. Dekkers received his Ph.D. and M.S. in chemical engineering from the University of Eindhoven and his B.S. in chemistry from the Radboud University, both in the Netherlands. - 自2021年6月完成业务合并以来，他一直担任Quantum-Si Incorporated董事会成员。自2017年5月以来，德克斯博士一直担任生命科学行业投资和咨询公司Novalis LifeSciences LLC的创始人和董事长。2010年1月至2016年5月，Dekkers博士担任德国勒沃库森拜耳公司的首席执行官，2002年至2009年，他担任赛默飞世尔科技公司。Dekkers博士目前担任乔治城大学国立卫生研究院基金会、Cerevel Therapeutics Holdings, Inc.、Ginkgo Bioworks Holdings, Inc.和AdBiome有限责任公司的董事。Dekkers博士曾于2017年3月至2021年9月担任Quanterix Corporation董事会成员。Dekkers博士在埃因霍温大学获得化学工程博士和硕士学位，在荷兰的拉德布德大学获得化学学士学位。
- Marijn Dekkers,has served on Quantum-Si Incorporated board of directors since the Closing of the Business Combination in June 2021. Since May 2017, Dr. Dekkers has served as a founder and the Chairman of Novalis LifeSciences LLC,an investment and advisory firm for the life sciences industry. From January 2010 to May 2016, Dr. Dekkers served as Chief Executive Officer of Bayer AG in Leverkusen, Germany, and from 2002 to 2009, he was chief executive officer of Thermo Fisher Scientific Inc. Dr. Dekkers currently serves on the board of directors of the Foundation for the National Institutes of Health, Georgetown University, Cerevel Therapeutics Holdings, Inc., Ginkgo Bioworks Holdings, Inc., and AdBiome LLC. Dr. Dekkers previously served on the board of directors of Quanterix Corporation from March 2017 to September 2021. Dr. Dekkers received his Ph.D. and M.S. in chemical engineering from the University of Eindhoven and his B.S. in chemistry from the Radboud University, both in the Netherlands.
- Harry E. Sloan
-
Harry E. Sloan，自2024年6月起担任Bold Eagle Acquisition Corp.联席主席。Sloan先生此前曾在2021年3月至2024年6月期间担任Bold Eagle Acquisition Corp.的董事长兼首席执行官。Sloan先生于2021年11月至2024年5月期间担任Screaming Eagle的董事长，直至Screaming Eagle完成与狮门电影公司的业务合并。Sloan先生继续担任狮门电影公司的董事。自2021年12月以来，Sloan先生一直担任Lions Gate Entertainment Corp.（NYSE：LGF.A，LGF.B）（“狮门影业的母公司”）的董事会成员，该公司是一家独立的电影和电视制作公司。Sloan先生曾担任Soaring Eagle的首席执行官兼董事长，该公司于2021年9月完成了与Ginkgo Bioworks，Inc.（纽约证券交易所代码：DNA）（“银杏”）的初步业务合并。Sloan先生仍然是银杏的董事。在Soaring Eagle之前，Sloan先生是Flying Eagle的首席执行官兼董事长，该公司在2020年3月的首次公开募股中筹集了690，000，000美元，并于2020年12月完成了与Skillz Inc.（纽约证券交易所代码：SKLZ）（“Skillz”）的初步业务合并，这是一家技术公司，使游戏开发商能够通过有趣且公平的多玩家竞争将其内容货币化。在加入飞鹰之前，Sloan先生是Diamond Eagle的创始投资者，该公司在2019年5月的首次公开募股中筹集了400，000，000美元，并于2020年4月完成了与DraftKings，Inc.（纳斯达克：DKNG）（“DraftKings”）的初始业务合并，后者是一家数字体育娱乐和游戏公司，该公司以其行业领先的每日梦幻体育和移动体育博彩平台而闻名，而SBTech（Global）Limited则是一家尖端体育博彩和游戏技术的国际统包供应商。Sloan先生现在担任DraftKings，Inc.的副董事长。在加入Diamond Eagle之前，Sloan先生是Platinum Eagle的创始投资者，该公司于2018年1月在首次公开发行股票时筹集了325，000，000美元，于2019年3月完成了与Target Logistics Management，LLC和RL Signor Holdings，LLC的初始业务合并，并更名为Target Hospitality Corp.TERM2TERM2（纳斯达克：TH）（“Target Hospitality”）是一家垂直整合的专业租赁和酒店服务公司。在加入Platinum Eagle之前，Sloan先生是Double Eagle的创始投资者，该公司在2015年9月的首次公开募股中筹集了500，000，000美元。双鹰股份于2017年11月完成企业合并，其中全资子公司收购Williams Scotsman90%的股权。在该交易中，Double Eagle更名为WillScot Corporation（“WSC”）。WSC是专业租赁服务市场的领导者，为北美各地的不同终端市场提供模块化空间和便携式存储解决方案。Sloan先生此前曾于2013年4月起担任Silver Eagle的董事长兼首席执行官，直至2015年3月完成与Videocon d2h有限公司（“Videocon”）的初步业务合并。2016年5月至2018年4月，Sloan先生在Videocon董事会任职，担任其提名、薪酬和薪酬委员会成员。Sloan先生还于2011年2月起至2013年1月业务合并完成前担任Global Eagle Acquisition Corp.的董事长兼首席执行官，并且他仍然是合并后公司Global Eagle Entertainment Inc.的董事。从2005年10月至2009年8月，Sloan先生担任电影、电视、家庭娱乐以及戏剧制作和发行公司Metro-Goldwyn-Mayer，Inc.（“MGM”）的董事长兼首席执行官，此后继续担任非执行董事长至2010年12月。MGM于2010年申请破产保护。1990年至2002年，Sloan先生担任欧洲广播集团SBS Broadcasting，S.A.（“SBS”）的董事长兼首席执行官，在西欧、中欧和东欧经营商业电视、付费频道、广播电台和相关印刷业务，他于1990年创立该公司并继续担任执行董事长至2005年。1999年，SBS成为狮门母公司的最大股东。Sloan先生在2004年4月至2005年3月期间担任Lions Gate Parent的董事会主席。从1983年到1989年，Sloan先生是新世界娱乐有限公司的联席主席，这是一家独立的电影和电视制作公司。此前，他曾在西班牙最大的媒体集团Promotora de Informaciones，S.A.（OTCMKTS：PRISY）和互动游戏和网页内容独立生产商ZeniMax Media Inc.的董事会任职。他目前在加州大学洛杉矶分校安德森管理学院访客委员会和加州大学洛杉矶分校戏剧、电影和电视执行委员会任职。Sloan先生获得了加州大学洛杉矶分校的学士学位和洛约拉法学院的法学博士学位。
Harry E. Sloan,is a founder, public company chief executive officer and a leading investor in the media, entertainment and technology industries. Mr. Sloan is the Chairman and CEO of Eagle Equity Partners II, LLC ("Eagle Equity"). Under Mr. Sloan's leadership, Eagle Equity has acquired and taken public, through special purpose acquisition companies, several digital media companies including, during 2020, DraftKings, Inc. (Nasdaq: DKNG) ("DraftKings") and Skillz Inc. (NYSE: SKLZ). Mr. Sloan has been at the forefront and evolution of the video gaming industry as one of the founding investors and a Board Member of Zenimax/Bethesda Game Studios, the studio acquired by Microsoft in March 2021. Mr. Sloan co-founded Soaring Eagle Acquisition Corp., which raised $1.725 billion in its initial public offering in February 2021, and in September 2021, completed its initial business combination with Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"). In January 2022, Mr. Sloan and his partners launched Screaming Eagle Acquisition Corp., which became Lionsgate Studios Corp. (Nasdaq: LION) in May 2024. Earlier in his career, Mr. Sloan was Chairman and Chief Executive Officer of MGM Studios and founded and led two public companies in the entertainment media arena, New World Entertainment and SBS Broadcasting, S.A. Mr. Sloan was also one of the founding investors of Lionsgate and served as Lionsgate's Non-Executive Chairman from 2004 to 2005. In May 2023, Mr. Sloan was appointed by President Biden as a member of the United States Holocaust Memorial Council.Mr. Sloan served as a director of Old Lionsgate from December 2021 to May 2025. Mr. Sloan served as a director of Legacy Lionsgate Studios from May 2024 to May 2025. Mr. Sloan has served as a director of Lionsgate Studios Corp. since May 2025 as a member of its Compensation Committee. Mr. Sloan is also a member of the Board of Directors and a member of the Audit Committee of Ginkgo, and Vice Chairman of the Board of Directors and Chair of the Nominating and Corporate Governance Committee of DraftKings. - Harry E. Sloan，自2024年6月起担任Bold Eagle Acquisition Corp.联席主席。Sloan先生此前曾在2021年3月至2024年6月期间担任Bold Eagle Acquisition Corp.的董事长兼首席执行官。Sloan先生于2021年11月至2024年5月期间担任Screaming Eagle的董事长，直至Screaming Eagle完成与狮门电影公司的业务合并。Sloan先生继续担任狮门电影公司的董事。自2021年12月以来，Sloan先生一直担任Lions Gate Entertainment Corp.（NYSE：LGF.A，LGF.B）（“狮门影业的母公司”）的董事会成员，该公司是一家独立的电影和电视制作公司。Sloan先生曾担任Soaring Eagle的首席执行官兼董事长，该公司于2021年9月完成了与Ginkgo Bioworks，Inc.（纽约证券交易所代码：DNA）（“银杏”）的初步业务合并。Sloan先生仍然是银杏的董事。在Soaring Eagle之前，Sloan先生是Flying Eagle的首席执行官兼董事长，该公司在2020年3月的首次公开募股中筹集了690，000，000美元，并于2020年12月完成了与Skillz Inc.（纽约证券交易所代码：SKLZ）（“Skillz”）的初步业务合并，这是一家技术公司，使游戏开发商能够通过有趣且公平的多玩家竞争将其内容货币化。在加入飞鹰之前，Sloan先生是Diamond Eagle的创始投资者，该公司在2019年5月的首次公开募股中筹集了400，000，000美元，并于2020年4月完成了与DraftKings，Inc.（纳斯达克：DKNG）（“DraftKings”）的初始业务合并，后者是一家数字体育娱乐和游戏公司，该公司以其行业领先的每日梦幻体育和移动体育博彩平台而闻名，而SBTech（Global）Limited则是一家尖端体育博彩和游戏技术的国际统包供应商。Sloan先生现在担任DraftKings，Inc.的副董事长。在加入Diamond Eagle之前，Sloan先生是Platinum Eagle的创始投资者，该公司于2018年1月在首次公开发行股票时筹集了325，000，000美元，于2019年3月完成了与Target Logistics Management，LLC和RL Signor Holdings，LLC的初始业务合并，并更名为Target Hospitality Corp.TERM2TERM2（纳斯达克：TH）（“Target Hospitality”）是一家垂直整合的专业租赁和酒店服务公司。在加入Platinum Eagle之前，Sloan先生是Double Eagle的创始投资者，该公司在2015年9月的首次公开募股中筹集了500，000，000美元。双鹰股份于2017年11月完成企业合并，其中全资子公司收购Williams Scotsman90%的股权。在该交易中，Double Eagle更名为WillScot Corporation（“WSC”）。WSC是专业租赁服务市场的领导者，为北美各地的不同终端市场提供模块化空间和便携式存储解决方案。Sloan先生此前曾于2013年4月起担任Silver Eagle的董事长兼首席执行官，直至2015年3月完成与Videocon d2h有限公司（“Videocon”）的初步业务合并。2016年5月至2018年4月，Sloan先生在Videocon董事会任职，担任其提名、薪酬和薪酬委员会成员。Sloan先生还于2011年2月起至2013年1月业务合并完成前担任Global Eagle Acquisition Corp.的董事长兼首席执行官，并且他仍然是合并后公司Global Eagle Entertainment Inc.的董事。从2005年10月至2009年8月，Sloan先生担任电影、电视、家庭娱乐以及戏剧制作和发行公司Metro-Goldwyn-Mayer，Inc.（“MGM”）的董事长兼首席执行官，此后继续担任非执行董事长至2010年12月。MGM于2010年申请破产保护。1990年至2002年，Sloan先生担任欧洲广播集团SBS Broadcasting，S.A.（“SBS”）的董事长兼首席执行官，在西欧、中欧和东欧经营商业电视、付费频道、广播电台和相关印刷业务，他于1990年创立该公司并继续担任执行董事长至2005年。1999年，SBS成为狮门母公司的最大股东。Sloan先生在2004年4月至2005年3月期间担任Lions Gate Parent的董事会主席。从1983年到1989年，Sloan先生是新世界娱乐有限公司的联席主席，这是一家独立的电影和电视制作公司。此前，他曾在西班牙最大的媒体集团Promotora de Informaciones，S.A.（OTCMKTS：PRISY）和互动游戏和网页内容独立生产商ZeniMax Media Inc.的董事会任职。他目前在加州大学洛杉矶分校安德森管理学院访客委员会和加州大学洛杉矶分校戏剧、电影和电视执行委员会任职。Sloan先生获得了加州大学洛杉矶分校的学士学位和洛约拉法学院的法学博士学位。
- Harry E. Sloan,is a founder, public company chief executive officer and a leading investor in the media, entertainment and technology industries. Mr. Sloan is the Chairman and CEO of Eagle Equity Partners II, LLC ("Eagle Equity"). Under Mr. Sloan's leadership, Eagle Equity has acquired and taken public, through special purpose acquisition companies, several digital media companies including, during 2020, DraftKings, Inc. (Nasdaq: DKNG) ("DraftKings") and Skillz Inc. (NYSE: SKLZ). Mr. Sloan has been at the forefront and evolution of the video gaming industry as one of the founding investors and a Board Member of Zenimax/Bethesda Game Studios, the studio acquired by Microsoft in March 2021. Mr. Sloan co-founded Soaring Eagle Acquisition Corp., which raised $1.725 billion in its initial public offering in February 2021, and in September 2021, completed its initial business combination with Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"). In January 2022, Mr. Sloan and his partners launched Screaming Eagle Acquisition Corp., which became Lionsgate Studios Corp. (Nasdaq: LION) in May 2024. Earlier in his career, Mr. Sloan was Chairman and Chief Executive Officer of MGM Studios and founded and led two public companies in the entertainment media arena, New World Entertainment and SBS Broadcasting, S.A. Mr. Sloan was also one of the founding investors of Lionsgate and served as Lionsgate's Non-Executive Chairman from 2004 to 2005. In May 2023, Mr. Sloan was appointed by President Biden as a member of the United States Holocaust Memorial Council.Mr. Sloan served as a director of Old Lionsgate from December 2021 to May 2025. Mr. Sloan served as a director of Legacy Lionsgate Studios from May 2024 to May 2025. Mr. Sloan has served as a director of Lionsgate Studios Corp. since May 2025 as a member of its Compensation Committee. Mr. Sloan is also a member of the Board of Directors and a member of the Audit Committee of Ginkgo, and Vice Chairman of the Board of Directors and Chair of the Nominating and Corporate Governance Committee of DraftKings.
- Arie Belldegrun
-
Arie Belldegrun，他是Allogene Therapeutics（公共生物制药公司）的联合创始人，并自2017年11月起担任其董事会执行主席。2014年3月至2017年10月，Belldegrun博士担任Kite Pharma， Inc.的总裁兼首席执行官，2009年6月至2017年10月担任其董事会成员。他也是Gingko Bioworks的董事（从2021年9月到2024年11月）。Belldegrun博士目前担任Bellco Capital LLC的董事长（自2004年以来）；Two River董事长兼合伙人（2009年6月起）；Breakthrough Properties LLC和Breakthrough Services， L.L.C.联合主席（自2019年4月起）；Kronos Bio董事长（自2017年11月起）；Symbiotic Capital联席主席（自2023年6月起）；ByHeart, Inc.的董事（自2019年10月起）。Belldegrun博士也是Vida Ventures， LLC的高级常务董事（自2017年11月以来）。Belldegrun博士是一名研究教授，拥有泌尿肿瘤学的Roy和Carol Doumani主席，也是加州大学洛杉矶分校David Geffen医学院泌尿肿瘤学研究所的创始人和主任。加入UCLA之前，Belldegrun博士在National Cancer Institute/NIH担任Steven a . Rosenberg博士的外科肿瘤学和免疫疗法研究员。他在耶路撒冷的Hebrew大学哈达萨医学院完成了医学博士学位，在Weizmann Institute of Science完成了免疫学研究生学习，并在哈佛医学院完成了泌尿外科住院医师。他撰写了几本肿瘤学书籍，并撰写了500多篇与泌尿系统癌症、免疫治疗、基因治疗和癌症疫苗相关的科学和医学论文。他获得了美国泌尿外科委员会和美国泌尿生殖外科医生协会的认证。
Arie Belldegrun,is a co-founder of Allogene Therapeutics, a public biopharmaceutical company, and has served as Executive Chairman of its board of directors since November 2017. From March 2014 until October 2017, Dr. Belldegrun served as the President and Chief Executive Officer of Kite Pharma, Inc. and as a member of its board of directors from June 2009 until October 2017. He was also a Director of Gingko Bioworks (from September 2021 to November 2024). Dr. Belldegrun currently serves as Chairman of Bellco Capital LLC (since 2004); Chairman and Partner of Two River (since June 2009); Co-chairman of Breakthrough Properties LLC and Breakthrough Services, L.L.C. (since April 2019); Chairman of Kronos Bio (since November 2017); Co-chairman of Symbiotic Capital (since June 2023); and Director of ByHeart, Inc. (since October 2019). Dr. Belldegrun is also Senior Managing Director of Vida Ventures, LLC (since November 2017). Dr. Belldegrun is a Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Founder and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, Dr. Belldegrun was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School. He has authored several books on oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy and cancer vaccines. He is certified by the American Board of Urology and the American Association of Genitourinary Surgeons. - Arie Belldegrun，他是Allogene Therapeutics（公共生物制药公司）的联合创始人，并自2017年11月起担任其董事会执行主席。2014年3月至2017年10月，Belldegrun博士担任Kite Pharma， Inc.的总裁兼首席执行官，2009年6月至2017年10月担任其董事会成员。他也是Gingko Bioworks的董事（从2021年9月到2024年11月）。Belldegrun博士目前担任Bellco Capital LLC的董事长（自2004年以来）；Two River董事长兼合伙人（2009年6月起）；Breakthrough Properties LLC和Breakthrough Services， L.L.C.联合主席（自2019年4月起）；Kronos Bio董事长（自2017年11月起）；Symbiotic Capital联席主席（自2023年6月起）；ByHeart, Inc.的董事（自2019年10月起）。Belldegrun博士也是Vida Ventures， LLC的高级常务董事（自2017年11月以来）。Belldegrun博士是一名研究教授，拥有泌尿肿瘤学的Roy和Carol Doumani主席，也是加州大学洛杉矶分校David Geffen医学院泌尿肿瘤学研究所的创始人和主任。加入UCLA之前，Belldegrun博士在National Cancer Institute/NIH担任Steven a . Rosenberg博士的外科肿瘤学和免疫疗法研究员。他在耶路撒冷的Hebrew大学哈达萨医学院完成了医学博士学位，在Weizmann Institute of Science完成了免疫学研究生学习，并在哈佛医学院完成了泌尿外科住院医师。他撰写了几本肿瘤学书籍，并撰写了500多篇与泌尿系统癌症、免疫治疗、基因治疗和癌症疫苗相关的科学和医学论文。他获得了美国泌尿外科委员会和美国泌尿生殖外科医生协会的认证。
- Arie Belldegrun,is a co-founder of Allogene Therapeutics, a public biopharmaceutical company, and has served as Executive Chairman of its board of directors since November 2017. From March 2014 until October 2017, Dr. Belldegrun served as the President and Chief Executive Officer of Kite Pharma, Inc. and as a member of its board of directors from June 2009 until October 2017. He was also a Director of Gingko Bioworks (from September 2021 to November 2024). Dr. Belldegrun currently serves as Chairman of Bellco Capital LLC (since 2004); Chairman and Partner of Two River (since June 2009); Co-chairman of Breakthrough Properties LLC and Breakthrough Services, L.L.C. (since April 2019); Chairman of Kronos Bio (since November 2017); Co-chairman of Symbiotic Capital (since June 2023); and Director of ByHeart, Inc. (since October 2019). Dr. Belldegrun is also Senior Managing Director of Vida Ventures, LLC (since November 2017). Dr. Belldegrun is a Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Founder and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, Dr. Belldegrun was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School. He has authored several books on oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy and cancer vaccines. He is certified by the American Board of Urology and the American Association of Genitourinary Surgeons.
高管简历
中英对照 | 中文 | 英文- Jason Kelly
Jason Kelly，我们的创始人之一，自2008年成立以来担任我们的董事会成员和首席执行官。Kelly博士曾担任CM Life Sciences IIInc.董事纳斯达克:CMII，一家专注于生命科学领域的特殊目的收购公司，自2021年2月首次公开募股以来。Kelly博士拥有麻省理工学院生物工程博士学位和化学工程和生物学学士学位。
Jason Kelly,one of our founders, has served as a member of our board of directors and as the Chief Executive Officer since Ginkgo’s founding in 2008. Dr. Kelly has served as a director of CM Life Sciences II Inc. Nasdaq: CMII, a special purpose acquisition company with a focus on the life sciences sector, since its initial public offering in February 2021. Dr. Kelly has a Ph.D. in Biological Engineering and a B.S. in Chemical Engineering and Biology from the Massachusetts Institute of Technology.- Jason Kelly，我们的创始人之一，自2008年成立以来担任我们的董事会成员和首席执行官。Kelly博士曾担任CM Life Sciences IIInc.董事纳斯达克:CMII，一家专注于生命科学领域的特殊目的收购公司，自2021年2月首次公开募股以来。Kelly博士拥有麻省理工学院生物工程博士学位和化学工程和生物学学士学位。
- Jason Kelly,one of our founders, has served as a member of our board of directors and as the Chief Executive Officer since Ginkgo’s founding in 2008. Dr. Kelly has served as a director of CM Life Sciences II Inc. Nasdaq: CMII, a special purpose acquisition company with a focus on the life sciences sector, since its initial public offering in February 2021. Dr. Kelly has a Ph.D. in Biological Engineering and a B.S. in Chemical Engineering and Biology from the Massachusetts Institute of Technology.
- Reshma Shetty
Reshma Shetty，我们的创始人之一，自2008年成立以来担任我们的董事会成员，总裁兼首席运营官。谢蒂博士目前在非营利组织“核威胁倡议”的生物咨询小组任职。谢蒂博士拥有麻省理工学院生物工程博士学位和犹他大学计算机科学学士学位。
Reshma Shetty,one of our founders, has served as a member of our board of directors and as President and Chief Operating Officer since Ginkgo’s founding in 2008. Dr. Shetty currently serves on the Bio Advisory Group at the non-profit Nuclear Threat Initiative. Dr. Shetty has a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology and a B.S. in Computer Science from the University of Utah.- Reshma Shetty，我们的创始人之一，自2008年成立以来担任我们的董事会成员，总裁兼首席运营官。谢蒂博士目前在非营利组织“核威胁倡议”的生物咨询小组任职。谢蒂博士拥有麻省理工学院生物工程博士学位和犹他大学计算机科学学士学位。
- Reshma Shetty,one of our founders, has served as a member of our board of directors and as President and Chief Operating Officer since Ginkgo’s founding in 2008. Dr. Shetty currently serves on the Bio Advisory Group at the non-profit Nuclear Threat Initiative. Dr. Shetty has a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology and a B.S. in Computer Science from the University of Utah.
- Mark Dmytruk
Mark Dmytruk自2020年11月起担任Ginkgo的首席财务官。从2017年到2020年，Dmytruk先生担任Syneos Health公司的执行副总裁，负责公司战略和发展，Syneos Health是一家服务于生物制药行业的全球合同研究组织和合同商业组织。Syneos Health于2017年由Inventiv Health和Inc Research合并而成，合并前，Dmytruk先生于2014年至2017年在Inventiv Health担任办公室主任，2011年至2014年担任患者结果部门总裁。在Inventiv Health之前，从2001年到2011年，Dmytruk先生在赛默飞世尔科学公司（Thermo Fisher Scientific）及其前身飞世尔科学公司（Fisher Scientific）担任过各种职务。作为公司发展的副总裁，Dmytruk先生领导公司的M&A职能，为其改变行业的战略和转型增长做出了贡献。他也曾担任Thermo Fisher Scientific的Athena Diagnostics业务单元的财务副总裁，此前该公司被出售给Quest Diagnostics。德米特鲁克的职业生涯始于加拿大安永会计师事务所（Ernst&Young）。Dmytruk先生拥有麻省理工学院斯隆管理学院的工商管理硕士学位和阿尔伯塔大学的商业学士学位。
Mark Dmytruk,has been the Chief Financial Officer of Ginkgo since November 2020. From 2017 to 2020 Mr. Dmytruk served as Executive Vice President, Corporate Strategy and Development, for Syneos Health, a global Contract Research Organization and Contract Commercial Organization serving the biopharmaceutical industry. Syneos Health was formed through the merger of inVentiv Health and INC Research in 2017 and prior to the merger Mr. Dmytruk served at inVentiv Health as Chief of Staff from 2014 to 2017 and President, Patient Outcomes Division, from 2011 to 2014. Prior to inVentiv Health, Mr. Dmytruk served in a variety of roles at Thermo Fisher Scientific and its predecessor, Fisher Scientific from 2001 to 2011. As Vice President of Corporate Development, Mr. Dmytruk led the company’s M&A function, contributing to its industry-changing strategy and transformational growth. He also served as Vice President of Finance for the Athena Diagnostics business unit of Thermo Fisher Scientific prior to its sale to Quest Diagnostics. Mr. Dmytruk began his career at Ernst & Young in Canada. Mr. Dmytruk has an M.B.A. from the Sloan School of Management at the Massachusetts Institute of Technology and a Bachelor of Commerce from the University of Alberta.- Mark Dmytruk自2020年11月起担任Ginkgo的首席财务官。从2017年到2020年，Dmytruk先生担任Syneos Health公司的执行副总裁，负责公司战略和发展，Syneos Health是一家服务于生物制药行业的全球合同研究组织和合同商业组织。Syneos Health于2017年由Inventiv Health和Inc Research合并而成，合并前，Dmytruk先生于2014年至2017年在Inventiv Health担任办公室主任，2011年至2014年担任患者结果部门总裁。在Inventiv Health之前，从2001年到2011年，Dmytruk先生在赛默飞世尔科学公司（Thermo Fisher Scientific）及其前身飞世尔科学公司（Fisher Scientific）担任过各种职务。作为公司发展的副总裁，Dmytruk先生领导公司的M&A职能，为其改变行业的战略和转型增长做出了贡献。他也曾担任Thermo Fisher Scientific的Athena Diagnostics业务单元的财务副总裁，此前该公司被出售给Quest Diagnostics。德米特鲁克的职业生涯始于加拿大安永会计师事务所（Ernst&Young）。Dmytruk先生拥有麻省理工学院斯隆管理学院的工商管理硕士学位和阿尔伯塔大学的商业学士学位。
- Mark Dmytruk,has been the Chief Financial Officer of Ginkgo since November 2020. From 2017 to 2020 Mr. Dmytruk served as Executive Vice President, Corporate Strategy and Development, for Syneos Health, a global Contract Research Organization and Contract Commercial Organization serving the biopharmaceutical industry. Syneos Health was formed through the merger of inVentiv Health and INC Research in 2017 and prior to the merger Mr. Dmytruk served at inVentiv Health as Chief of Staff from 2014 to 2017 and President, Patient Outcomes Division, from 2011 to 2014. Prior to inVentiv Health, Mr. Dmytruk served in a variety of roles at Thermo Fisher Scientific and its predecessor, Fisher Scientific from 2001 to 2011. As Vice President of Corporate Development, Mr. Dmytruk led the company’s M&A function, contributing to its industry-changing strategy and transformational growth. He also served as Vice President of Finance for the Athena Diagnostics business unit of Thermo Fisher Scientific prior to its sale to Quest Diagnostics. Mr. Dmytruk began his career at Ernst & Young in Canada. Mr. Dmytruk has an M.B.A. from the Sloan School of Management at the Massachusetts Institute of Technology and a Bachelor of Commerce from the University of Alberta.